<DOC>
	<DOC>NCT02324491</DOC>
	<brief_summary>The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adult subjects with type 2 diabetes mellitus.</brief_summary>
	<brief_title>An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Phase 2, randomized, double-blind, placebo-controlled, parallel dose arms study with 12-month randomized treatment.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Obese with BMI â‰¥30 kg/m2 Type 2 diabetes mellitus HbA1c of 711% Fasting glucose &lt;15.5 mmol/L Treated with diet and exercise alone or with a stable regimen of metformin, sulfonylurea, pioglitazone, DPP4 inhibitor, GLP1 receptor agonist, SGLT2 inhibitor or any combination of these agents Female subjects must be surgically sterile, postmenopausal or using longacting contraception, which includes intrauterine devices or use of an implanted or injectable contraceptive Current or recent use of insulin Severe hypoglycemia within the prior 6 months Metabolic disorders or genetic disorders linked to obesity (e.g., PraderWilli Syndrome)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>